Meldonium-solofarm Injection 100mg / 5ml 10 mL pc


Meldonium-solofarm Injection 100mg / 5ml 10 mL pc



Active substance:
1 ml of solution contains: 100 mg of meldonium dihydrate.
Water for injections to 1 mL.
Transparent colorless liquid.
Product form:
Injection of 100 mg / ml.
5 mL vials of low density polyethylene or polypropylene.
5 or 10 vials together with instructions for use in a stack of cardboard.
Hypersensitivity to the drug, increased intracranial pressure (in violation of the venous drainage, intracranial tumors), age 18 years (effectiveness and safety have not been established), pregnancy, breastfeeding.
When the liver and / or kidney.
100 mg / ml
In the treatment of coronary heart disease (angina, myocardial infarction); Chronic heart failure and cardiomyopathy in the background dishormonal violations, as well as in the treatment of acute and chronic disorders of cerebral blood flow (stroke and cerebrovascular insufficiency).
Hemophthalmus and retinal hemorrhages of varying etiology, thrombosis, central retinal vein and its branches, retinopathy of different etiologies (idiopathic and diabetic).
Reduced performance; mental and physical overload (including athletes). The drug can produce a positive result in the doping control (see. Section “Special Instructions”).
withdrawal syndrome in chronic alcoholism (in combination with specific alcoholism therapy).
Interaction with other drugs
It can be combined with antianginal agents, anticoagulants, antiplatelet agents, antiarrhythmic agents, diuretics, bronchodilators. It enhances the effect of cardiac glycosides. Due to the possible development of moderate tachycardia and hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, antihypertensives and other peripheral vasodilators, since meldonium amplifies their effect.
Symptoms: decrease in blood pressure accompanied by headache, palpitations, dizziness and general weakness.
Treatment: symptomatic. The drug has low toxicity and does not cause adverse reactions that are dangerous to the health of patients.
pharmachologic effect
Pharmacological group:
Metabolic means.
Meldonium – structural analog of gamma-butyrobetaine – a substance that is found in every cell of the human body. In high load conditions meldonium restores the balance between the delivery and demand of cells in oxygen, eliminates the accumulation of toxic products of metabolism in the cells, protecting them from damage; also exerts a tonic effect. As a result of its use of the body gains the ability to withstand stress and quickly restore energy reserves. Because of these properties meldonium used to treat a variety of disorders of the cardiovascular system, brain blood supply, as well as to improve physical and mental performance. By lowering the concentration of carnitine intensively synthesized gamma-butyrobetaine possesses vasodilating properties. In the case of acute myocardial ischemic injury meldonium inhibits the formation of necrotic zone shortens the rehabilitation period. In heart failure, improves exercise capacity, reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral blood circulation improves blood circulation in the ischemic focus, promotes redistribution of blood to the ischemic area. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during abstinence syndrome.
The bioavailability of the drug following intravenous administration is 100%. The maximum plasma concentration is reached immediately after its introduction. It is metabolized in the body into two major metabolites are excreted by the kidneys. The half-life (T1 / 2) is 3-6 hours.
Pregnancy and breast-feeding
Health and Safety in pregnant women has not been studied in order to avoid possible adverse effects on the fetus, its use is contraindicated. Isolation of the drug with milk and its effect on the health of the newborn have not been studied, so, if you must use, should stop breastfeeding.
Conditions of supply of pharmacies
side effects
Depending on the frequency of occurrence of the following groups of undesirable side reactions by the WHO: very often (> 1/10); often (> 1/100 to 1/1000 to 1/10000 to
special instructions
Years of experience in the treatment of acute myocardial infarction and unstable angina Cardiac offices shows that meldonium preparation is not I a number of acute coronary syndrome and its use is not absolutely necessary. On January 1, 2016 meldonium included in the list of the World Anti-Doping Agency banned substances.
The effect on the ability of control of vehicles and mechanisms
No evidence of adverse effects of the drug on the rate of psychomotor reactions.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
In view of the possibility of bringing a drug effect it is recommended to use in the morning. The drug is administered intramuscularly, intravenously and parabulbarly. The method of administration, the dose and duration of treatment is determined individually depending on the indication, severity of the condition and others.
Cardiovascular diseases
In the combined therapy: – ischemic heart disease (myocardial infarction) intravenously by 0.5-1.0 g per day (5-10 ml of the drug); – coronary heart disease (stable angina), congestive heart failure and cardiomyopathy violations amid dishormonal intravenously at 0.5-1.0 g per day (5.10 ml of the preparation), or intramuscularly at 0.5 g 1-2 times day course of treatment 10-14 days, followed by transfer to a reception inside.
The total course of treatment 4-6 weeks.
Cerebrovascular accidents
In the combined therapy in the acute phase of 0.5 g (5 ml preparation) 1 intravenously once a day for 10 days, passing to intake of 0.5-1.0 g
The total course of treatment 4-6 weeks.
In chronic cerebral circulatory insufficiency (vascular encephalopathy) 0.5 g (5 ml drug) intramuscularly or intravenously 1 times a day for 10 days, followed by 0.5 g orally.
The total course of treatment 4-6 weeks. Repeated courses (usually 2-3 times a year) are possible after consultation with the doctor.
Oftalmopatologiya (hemophthalmus and retinal hemorrhages of varying etiology, thrombosis, central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertensive)).
0.05 g (0.5 ml preparation) parabulbarly for 10 days. Including used as part of combination therapy.
Mental and physical overload
0.5 g (5 ml drug) intramuscularly or intravenously 1 time per day. The course of treatment 10-14 days. If necessary, repeat the course in 2-3 weeks
Chronic alcoholism 0.5 g (5 ml drug) intramuscularly or intravenously 2 times per day. The course of treatment 7-10 days
Working with the polymer vial: 1. Take a vial and shake it, holding it by the neck. 2. surrendering ampoule hand, when it should not be liberated drug and rotating movements rotate and separate valve. 3. Through the hole immediately connect a syringe with an ampoule. 4. Turn the vial and syringe dial slowly in its contents. 5. Push the needle on the syringe.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

Grotex Ltd.

There are no reviews yet.

Add your review